NCT06771128

Brief Summary

the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
398

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 7, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 13, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

January 13, 2026

Status Verified

September 1, 2025

Enrollment Period

1.1 years

First QC Date

January 7, 2025

Last Update Submit

January 9, 2026

Conditions

Nocturnal Enuresis in ChildrenDesmopressinMonosymptomatic Nocturnal Enuresis

Keywords

monosymptomatic nocturnal enuresisnocturnal enuresisdesmopressinGinkgo Biloba

Outcome Measures

Primary Outcomes (1)

  • Night wetting frequency

    Night wetting frequency is measured by the number of wet nights per week.

    1, 3 months

Study Arms (4)

Ginkgo Biloba group

EXPERIMENTAL

Patients in this group receive Ginkgo Biloba oral tablet.

Drug: Ginkgo Biloba oral tabletDrug: Desmopressin like Placebo

Desmopressin group

ACTIVE COMPARATOR

Patients in this group receive Desmopressin oral tablets.

Drug: Desmopressin Acetate 0.2 mg TabletsDrug: Ginkgo Biloba like Placebo

Combination group

EXPERIMENTAL

Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.

Drug: Ginkgo Biloba oral tabletDrug: Desmopressin Acetate 0.2 mg Tablets

Placebo group

PLACEBO COMPARATOR

Patients in this group receive Placebo oral tablet.

Drug: Ginkgo Biloba like PlaceboDrug: Desmopressin like Placebo

Interventions

Ginkgo Biloba oral tabletDRUG

patients receive Ginkgo Biloba oral tablet 120 mg once daily

Combination groupGinkgo Biloba group
Desmopressin Acetate 0.2 mg TabletsDRUG

patient receives desmopressin 0.2 mg oral tablet once daily

Combination groupDesmopressin group
Ginkgo Biloba like PlaceboDRUG

patients receive Ginkgo Biloba like Placebo oral tablet once daily

Desmopressin groupPlacebo group
Desmopressin like PlaceboDRUG

patients receive Desmopressin like Placebo oral tablet once daily

Ginkgo Biloba groupPlacebo group

Eligibility Criteria

Age5 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • all children with monosymptomatic nocturnal enuresis.

You may not qualify if:

  • children with day and night wetting.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Menoufia Faculty of Medicine

Shebin El-Kom, Menoufia, 32511, Egypt

Location

MeSH Terms

Conditions

Nocturnal Enuresis

Interventions

Ginkgo ExtractDeamino Arginine Vasopressin

Condition Hierarchy (Ancestors)

EnuresisUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesBehavioral SymptomsBehaviorElimination DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Plant ExtractsPlant PreparationsBiological ProductsComplex MixturesArginine VasopressinVasopressinsPituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsOligopeptidesNerve Tissue ProteinsProteins

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

January 7, 2025

First Posted

January 13, 2025

Study Start

November 1, 2024

Primary Completion

December 1, 2025

Study Completion

January 1, 2026

Last Updated

January 13, 2026

Record last verified: 2025-09

Locations

EG(1)